Comparing Cell-Based and Egg-Based Influenza Vaccines for Hospitalization Prevention
Author Information
Author(s): Emily Rayens, Jennifer H. Ku, Lina S. Sy, Lei Qian, Bradley K. Ackerson, Yi Luo, Julia E. Tubert, Gina S. Lee, Punam P. Modha, Yoonyoung Park, Tianyu Sun, Evan J. Anderson, Hung Fu Tseng
Primary Institution: Kaiser Permanente Southern California
Hypothesis
What is the comparative vaccine effectiveness of cell-based versus egg-based influenza vaccines in preventing hospitalization during the 2022–2023 season among adults aged 18–64?
Conclusion
Cell-based and egg-based influenza vaccines provide similar protection against hospitalization due to influenza in adults aged 18–64 during the 2022–2023 season.
Supporting Evidence
- Cell-based vaccines were administered slightly earlier than egg-based vaccines.
- All PCR-confirmed hospitalizations were caused by influenza A.
- The study used a large cohort with comprehensive demographic and clinical data.
Takeaway
This study looked at two types of flu vaccines to see which one works better at keeping people out of the hospital. It found that both types are about equally good.
Methodology
This was a retrospective cohort study using electronic health records to compare the effectiveness of cell-based and egg-based influenza vaccines in preventing hospitalizations.
Potential Biases
Potential for residual confounding despite adjustments made in the analysis.
Limitations
Some vaccination data may have been missed, and the study may not be generalizable to all populations.
Participant Demographics
Adults aged 18–64, predominantly from Kaiser Permanente Southern California, with a diverse racial and ethnic background.
Statistical Information
Confidence Interval
−49.8%, 37.8%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website